2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.02B.01 PIK3C2A Potentiates Angiogenesis of Non-Small Cell Lung Cancer by Regulating ADRB2/VEGFA Signaling Pathway

EP.02B.01 PIK3C2A Potentiates Angiogenesis of Non-Small Cell Lung Cancer by Regulating ADRB2/VEGFA Signaling Pathway

Pdf Summary

The study investigates the role of PIK3C2A in promoting angiogenesis in non-small cell lung cancer (NSCLC) by regulating the ADRB2/VEGA signaling pathway. NSCLC is a highly aggressive cancer with a poor prognosis, and there is growing evidence implicating ADRB2 in cancer growth, angiogenesis, and metastasis. However, the precise molecular mechanisms remain unclear. The objective of this study was to elucidate these mechanisms and identify potential targets for NSCLC therapy.<br /><br />The research involved data analysis from multiple databases and conducted experiments like Co-immunoprecipitation (Co-IP), Immunofluorescence (IF), Western Blot (WB), and Polymerase Chain Reaction (PCR) to explore protein interactions and their effects on NSCLC angiogenesis. The results demonstrated that PIK3C2A interacts with the beta-2 adrenergic receptor (B2AR) and its expression is positively correlated with ADRB2 in NSCLC. Knocking down PIK3C2A reduced the expression of vascular endothelial growth factor A (VEGA), highlighting its role in angiogenesis.<br /><br />The study confirmed through immunohistochemistry that PIK3C2A expression correlates with increased microvessel density in NSCLC tissues. Findings suggest that PIK3C2A and ADRB2 collaboratively enhance NSCLC angiogenesis, making them promising biomarkers and therapeutic targets. Future research should involve in vitro and in vivo experiments to further explore the treatment potential of PIK3C2A inhibitors, which could slow tumor progression and improve patient outcomes.<br /><br />Overall, PIK3C2A has significant potential in NSCLC therapy by offering a new strategy to inhibit angiogenesis, potentially improving prognosis and extending survival for patients with this type of lung cancer.

Asset Subtitle

Ting Wang

Meta Tag

Speaker Ting Wang

Topic Tumor Biology – Preclinical Biology

Keywords

PIK3C2A

NSCLC

angiogenesis

ADRB2

VEGA signaling pathway

cancer therapy

biomarkers

protein interactions

therapeutic targets

lung cancer